Ilaris "switches off" periodic syndromes in Phase III study
This article was originally published in Scrip
Executive Summary
Novartis's injectable fully humanised monoclonal antibody, Ilaris (canakinumab) has been shown to send 90% of patients with cryopyrin-associated periodic syndromes (CAPS) into remission in a Phase III study, published in the NEJM online of June 4th.